| Identification | Back Directory | [Name]
S-GBOXIN | [CAS]
2101317-21-7 | [Synonyms]
S-GBOXIN
1H-Benzimidazolium,1-methyl-3-[2-[[(1R,2S,5R)-5-methyl-2-(1-methylethyl)cyclohexyl]oxy]-2-oxoethyl]-2-[3-(trifluoromethyl)phenyl]-,iodide(1:1) | [Molecular Formula]
C??H??F?IN?O? | [MDL Number]
MFCD32199204 | [MOL File]
2101317-21-7.mol | [Molecular Weight]
600.46 |
| Hazard Information | Back Directory | [Uses]
S-Gboxin is the active analogue of Gboxin; potent antitumor activity. | [in vivo]
S-Gboxin retains excellent metabolic stability, enhanced plasma stability, and PK-properties suitable for in vivo studies. S-Gboxin (10 mg/kg/day; intraperitoneally) inhibits glioblastoma (GBM) growth in vivo[1]. | Animal Model: | Female nude mice (6 to 9 weeks)[1] | | Dosage: | 10 mg/kg/day | | Administration: | Administered intraperitoneally; daily; 3 or 14 days | | Result: | Resulted in significant attenuation of growth and decreased cellular density compared to controls. |
|
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 13348960310; |
| Website: |
https://www.weikeqi-biotech.com/ |
|